of Generative AI
for Pharma:


About the project

As GenAI evolves at a record pace, pharma commercial teams must keep pace without losing sight of the overall business strategy. Understanding, testing, and extracting value from GenAI is critical for the majority of commercial teams across the pharmaceutical, bio, and life sciences landscape today.

The potential impact of GenAI within pharma ranges from MLR, creative, audience building, targeting, patient support programs, field force content optimization, as well as the broader category of customer experience programs with both patients and physicians.

Expert Insights:

A Conversation with Michael Sivak
by Mark Bard, Co-Founder, DHC Group

Combining GenAI with CX for Business Strategy and Value
by Rich Schwartz, Life Sciences Industry Practice Lead, Qualtrics

GenAI and Programmatic Media, Audiences, and Effectiveness
by Louis Naimoli VP, Programmatic, Haymarket Media

Navigating the AI Landscape in Pharma: The Imperative of Cross-Functional Collaboration
by Bob Brooks, Formerly of Relevate Health, GSK, and IQVIA
Table of Contents and Included Experts

Pharma Voices on AI in the Next Twelve Months
with Ericka Higgins-Tothe, Novo Nordisk
Michael Rowbotham, Pfizer
Michael Sivak, AstraZeneca